(Q52730629)

6 May 2018

title

In vivo and ex vivo assessment of the interaction between ivermectin and danofloxacin in sheep. (English)

1 reference

6 May 2018

0 references

Mariana Ballent

1

1 reference

6 May 2018

Adrián Lifschitz

2

1 reference

6 May 2018

Guillermo Virkel

3

1 reference

6 May 2018

Juan Sallovitz

4

1 reference

6 May 2018

Laura Maté

5

1 reference

6 May 2018

Carlos Lanusse

6

1 reference

6 May 2018

publication date

12 November 2011

1 reference

6 May 2018

published in

The Veterinary Journal

1 reference

6 May 2018

volume

192

1 reference

6 May 2018

issue

3

1 reference

6 May 2018

page(s)

422-427

1 reference

6 May 2018

Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of danofloxacin in sheep biological fluids

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Involvement of P-glycoprotein on ivermectin kinetic behaviour in sheep: itraconazole-mediated changes on gastrointestinal disposition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Liquid chromatographic determination of ivermectin in animal plasma with trifluoroacetic anhydride and N-methylimidazole as the derivatization reagent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Pharmacokinetics of danofloxacin 18% in lactating sheep and goats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

What is the true risk of a pharmacokinetic drug-drug interaction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Active secretion of the fluoroquinolone ciprofloxacin by human intestinal epithelial Caco-2 cell layers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Ivermectin interacts with human ABCG2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Intestinal secretion is a major route for parent ivermectin elimination in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Human jejunal effective permeability and its correlation with preclinical drug absorption models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Moxidectin in cattle: correlation between plasma and target tissues disposition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Loperamide modifies the tissue disposition kinetics of ivermectin in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Cattle nematodes resistant to macrocyclic lactones: comparative effects of P-glycoprotein modulation on the efficacy and disposition kinetics of ivermectin and moxidectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Interference with P-glycoprotein improves ivermectin activity against adult resistant nematodes in sheep

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Pharmacokinetics and tissue disposition of danofloxacin in sheep.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Combined subcutaneous administration of ivermectin and nitroxynil in sheep: age/body weight related changes to the kinetic disposition of both compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Pharmacokinetics of ivermectin in pregnant and nonpregnant sheep.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Involvement of breast cancer resistance protein (BCRP/ABCG2) in the secretion of danofloxacin into milk: interaction with ivermectin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

P-glycoprotein-mediated transport of oxytetracycline in the Caco-2 cell model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2011.09.006

10.1016/J.TVJL.2011.09.006

7 January 2021

Identifiers

DOI

1 reference

6 May 2018

PubMed ID

22079145

1 reference

6 May 2018